Abstract: A structure for the front of a vehicle body includes left and right front-side frames extending in the longitudinal direction thereof, a front bulkhead provided between the front ends of said left and right front-side frames; and a bumper laid out in front of said front bulkhead. Left and right side bulkhead members include left and right front walls and left and right rear walls located behind said left and right front walls at a distance therefrom. The bumper overlaps the front surfaces of the left and right front walls. Left and right stays extend between the left and right front walls and the left and right rear walls. The front ends of said left and right stays, the left and right front walls, and the bumper are joined together. The rear ends of the left and right stays are joined to the left and right rear walls.

Abstract: A structure for the front of a vehicle body includes left and right front-side frames extending in the longitudinal direction thereof, a front bulkhead provided between the front ends of said left and right front-side frames; and a bumper laid out in front of said front bulkhead. Left and right side bulkhead members include left and right front walls and left and right rear walls located behind said left and right front walls at a distance therefrom. The bumper overlaps the front surfaces of the left and right front walls. Left and right stays extend between the left and right front walls and the left and right rear walls. The front ends of said left and right stays, the left and right front walls, and the bumper are joined together. The rear ends of the left and right stays are joined to the left and right rear walls.

Abstract: Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in which a porphyrin metal complex is clathrated in albumin, it was found that the compound efficiently improves decreases in blood flow in circulatory disorders and fully prevents or improves tissue damage, thus the invention was achieved. That is, the invention is directed to an agent for improving a circulatory disorder including a compound in which a porphyrin metal complex is clathrated in albumin.

Abstract: There is provided a radiosensitizer containing an iron compound, more specifically, a radiosensitizer containing an iron compound selected from an inorganoiron compound, such as iron chloride, iron oxide, iron hydroxide, and iron sulfate; and an organoiron compound, such as saccharated ferric oxide, iron citrate, iron gluconate, chondroitin sulfate/iron colloid, cideferron, ferrotrenine, iron fumarate, iron pyrophosphate, a porphyrin-iron complex, and an albumin incorporating porphyrin-iron complex.